U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H27FN4O3
Molecular Weight 426.4848
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PALIPERIDONE

SMILES

Cc1c(CCN2CCC(CC2)c3c4ccc(cc4on3)F)c(=O)n5CCCC(c5n1)O

InChI

InChIKey=PMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3

HIDE SMILES / InChI

Molecular Formula C23H27FN4O3
Molecular Weight 426.4848
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including http://dx.doi.org/10.4172/2161-1459.1000117

Paliperidone (9-OH-risperidone) is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Very common adverse effects are: headache, tachycardia, somnolence and insomnia.

CNS Activity

Curator's Comment:: Due to a hydroxyl group in position 9, paliperidone is less lipophilic than risperidone and crosses the blood-brain barrier less easily the parent drug. Experiments in knock-out mice have suggested that the brain entry of both risperidone and paliperidone may be limited by the presence in the blood-brain barrier of the P-glycoprotein, a multidrug efflux transporter, which has a slightly greater affinity for paliperidone than risperidone.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.5 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.214 ng × h/mL
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
410 ng × h/mL
6 mg 1 times / day steady-state, oral
dose: 6 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
257.3 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
44.9 day
75 mg × eq single, intramuscular
dose: 75 mg × eq
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
22.8 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PALIPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23 h
single, oral
PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
26%
single, oral
PALIPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Disc. AE: Lethargy, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Lethargy
Tachycardia
Hypokalemia
Dyskinesia
Dystonia
Sources: Page: p.210
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources: Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources: Page: p.47
Disc. AE: Loss of consciousness...
AEs leading to
discontinuation/dose reduction:
Loss of consciousness
Sources: Page: p.47
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
DLT: Motor tic...
Dose limiting toxicities:
Motor tic
Sources:
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Disc. AE: Depressive symptom, Psychotic disorder...
AEs leading to
discontinuation/dose reduction:
Depressive symptom (0.9%)
Psychotic disorder (0.9%)
Anxiety (0.4%)
Insomnia (0.4%)
Agitation (0.4%)
Abnormal dreams (0.4%)
Libido decreased (0.4%)
Substance abuse (0.4%)
Suicidal ideation (0.4%)
Paranoid schizophrenia (0.4%)
Akathisia (0.9%)
Headache (0.9%)
Dystonia (0.4%)
Dizziness (0.4%)
Tardive dyskinesia (0.4%)
Dyskinesia (0.4%)
Oromandibular dystonia (0.4%)
Extrapyramidal disorder (0.4%)
Erectile dysfunction (0.9%)
Amenorrhea (0.4%)
Ejaculation failure (0.4%)
Galactorrhea (0.4%)
Gynecomastia (0.4%)
Injection site pain (0.9%)
Chest discomfort (0.4%)
Weight increased (0.9%)
Semen volume decreased (0.4%)
Sources: Page: p.565
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Disc. AE: Dyskinesia, Dystonia...
AEs leading to
discontinuation/dose reduction:
Dyskinesia
Dystonia
Tremor
Diaphoresis
Tachycardia
Sources: Page: p.210
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack (grade 3-5)
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Intestinal stricture NOS
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Seizures
Sources: Page: p.1
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Stroke...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Stroke
Transient ischemic attack
Neuroleptic malignant syndrome
QT interval prolonged
Tardive dyskinesia
Hyperglycemia
Dyslipidemia
Weight gain
Hyperprolactinemia
Seizures
Orthostatic hypotension
Syncope
Leukopenia
Neutropenia
Agranulocytosis
Cognitive impairment
Motor dysfunction NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dyskinesia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Dystonia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Hypokalemia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Lethargy Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Tachycardia Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources: Page: p.210
unhealthy, 12
n = 1
Health Status: unhealthy
Condition: Developmental delay
Age Group: 12
Sex: M
Population Size: 1
Sources: Page: p.210
Loss of consciousness Disc. AE
252 mg single, oral
Overdose
Dose: 252 mg
Route: oral
Route: single
Dose: 252 mg
Sources: Page: p.47
unhealthy, 16
n = 1
Health Status: unhealthy
Condition: Conduct disorder
Age Group: 16
Sex: M
Population Size: 1
Sources: Page: p.47
Motor tic DLT
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 30
Sex: M
Population Size: 1
Sources:
Abnormal dreams 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Agitation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Amenorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Anxiety 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Chest discomfort 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dizziness 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Ejaculation failure 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Extrapyramidal disorder 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Galactorrhea 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Gynecomastia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Insomnia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Libido decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Oromandibular dystonia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Paranoid schizophrenia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Semen volume decreased 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Substance abuse 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Suicidal ideation 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Tardive dyskinesia 0.4%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Akathisia 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Depressive symptom 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Erectile dysfunction 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Headache 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Injection site pain 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Psychotic disorder 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Weight increased 0.9%
Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.565
unhealthy, 37.7
n = 226
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 37.7
Sex: M+F
Population Size: 226
Sources: Page: p.565
Diaphoresis Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Dyskinesia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Dystonia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Tachycardia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Tremor Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources: Page: p.210
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 38
Sex: M
Population Size: 1
Sources: Page: p.210
Agranulocytosis Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Cognitive impairment Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Dyslipidemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Hyperglycemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Hyperprolactinemia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Intestinal stricture NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Leukopenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Motor dysfunction NOS Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Neuroleptic malignant syndrome Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Neutropenia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Orthostatic hypotension Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
QT interval prolonged Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Seizures Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Stroke Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Syncope Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Tardive dyskinesia Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Weight gain Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Transient ischemic attack grade 3-5
Disc. AE
12 mg 1 times / day multiple, oral
Recommended
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.1
Agranulocytosis Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Cognitive impairment Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Dyslipidemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Hyperglycemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Hyperprolactinemia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Leukopenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Motor dysfunction NOS Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Neuroleptic malignant syndrome Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Neutropenia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Orthostatic hypotension Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
QT interval prolonged Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Seizures Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Stroke Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Syncope Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Tardive dyskinesia Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Transient ischemic attack Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Weight gain Disc. AE
234 mg 2 times / month multiple, intramuscular
Recommended
Dose: 234 mg, 2 times / month
Route: intramuscular
Route: multiple
Dose: 234 mg, 2 times / month
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Schizoaffective disorder
Sources: Page: p.1
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 61.9 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe detromethorphan
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe coumarin
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe chlorzoxazone
Page: 41, 81
no [Inhibition >30 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe lauric acid
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe Caffeine
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe phenytoin
Page: 41, 81
no [Inhibition >60 uM]
no (co-administration study)
Comment: examination of inhibition by paliperidone using CYP isozyme probe testosterone
Page: 41, 81
weak [IC50 63.26 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
2005 Dec
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
2005 Jul
Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
2005 May
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
2005 Nov
P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
2005 Oct
Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.
2005 Sep-Oct
Membrane transporter proteins: a challenge for CNS drug development.
2006
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
2006 Jul
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
2006 Mar
Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.
2006 Mar
Intestinal uptake and biodistribution of novel polymeric micelles after oral administration.
2006 Mar 10
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
2006 Oct
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
2007 Apr
Paliperidone: quo vadis?
2007 Apr
Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.
2007 Apr
Enantioselective analysis of the antipsychotic 9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs.
2007 Aug
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
2007 Dec 15
Possible neuroleptic malignant syndrome associated with paliperidone.
2007 Fall
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
2007 Feb
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
2007 Feb
FDA approves new antipsychotic.
2007 Feb 1
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
2007 Jan
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.
2007 Jan 29
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
2007 Jul
Molecule of the month. Paliperidone.
2007 Jun
Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
2007 Jun
Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.
2007 Jun 1
Paliperidone (Invega) for schizophrenia.
2007 Mar 12
New drug for schizophrenia.
2007 Mar-Apr
New drugs: paliperidone, dasatinib, and decitabine.
2007 Mar-Apr
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.
2007 Mar-Apr
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
2007 May
Paliperidone: a new extended-release oral atypical antipsychotic.
2007 Oct
Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis. Validation and determination of enantiomeric purity.
2007 Sep 7
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
2008
New drug update: 2007.
2008 Apr
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
2008 Jan
Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.
2008 Jul 1
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
2008 Jun
Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
2008 Jun
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
2008 May
Apparent seizure and atrial fibrillation associated with paliperidone.
2008 Nov 15
Gateways to clinical trials.
2008 Oct
Paliperidone extended-release for the treatment of schizophrenia.
2008 Oct
Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.
2008 Oct 3
Secondary delusional parasitosis treated with paliperidone.
2009 Apr
Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.
2009 Feb
Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.
2009 May
Patents

Patents

Sample Use Guides

In adults is 6 mg administered once daily In adolescents 12-17 years of age is 3 mg administered once daily
Route of Administration: Oral
Paliperidone has dual hyperprolactinemic actions in lactotrophs i) by preserving the coupling of spontaneous electrical activity and prolactin secretion in the presence of dopamine and ii) by inhibiting intrinsic dopamine receptor activity in the absence of dopamine, leading to enhanced calcium signaling and secretion.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:37:23 UTC 2021
Edited
by admin
on Fri Jun 25 20:37:23 UTC 2021
Record UNII
838F01T721
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PALIPERIDONE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PALIPERIDONE [USAN]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-
Systematic Name English
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
PALIPERIDONE [USP MONOGRAPH]
Common Name English
PALIPERIDONE [MART.]
Common Name English
PALIPERIDONE [EMA EPAR]
Common Name English
9-HYDROXYRISPERIDONE
Common Name English
RISPERIDONE SPECIFIED IMPURITY C [EP]
Common Name English
RO76477
Code English
PALIPERIDONE [WHO-DD]
Common Name English
PALIPERIDONE [INN]
Common Name English
PALIPERIDONE [VANDF]
Common Name English
(9RS)-3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDIN-1-YL))ETHYL)-9-HYDROXY-2-METHYL-6,7,8,9-TETRAHYDRO-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Common Name English
NSC-759623
Code English
PALIPERIDONE [ORANGE BOOK]
Common Name English
PALIPERIDONE [USP-RS]
Common Name English
PALIPERIDONE [MI]
Common Name English
RISPERIDONE IMPURITY, 9-HYDROXYRISPERIDONE- [USP]
Common Name English
R-76477
Code English
RO-76477
Code English
PALIPERIDONE [JAN]
Common Name English
INVEGA
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
WHO-VATC QN05AX13
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
LIVERTOX 732
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: PSYCHOTIC DISORDERS)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
EMA ASSESSMENT REPORTS INVEGA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
NCI_THESAURUS C66883
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4137
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
LACTMED
Paliperidone
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL1621
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EPA CompTox
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
WIKIPEDIA
PALIPERIDONE
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
DRUG BANK
DB01267
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
INN
7977
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
USP_CATALOG
1491809
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY USP-RS
CAS
144598-75-4
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
IUPHAR
7258
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
PUBCHEM
115237
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
RXCUI
679314
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C66293
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
FDA UNII
838F01T721
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
EVMPD
SUB23268
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
MERCK INDEX
M8357
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY Merck Index
HSDB
8148
Created by admin on Fri Jun 25 20:37:23 UTC 2021 , Edited by admin on Fri Jun 25 20:37:23 UTC 2021
PRIMARY
Related Record Type Details
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET->WEAK INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TRANSPORTER -> SUBSTRATE
TRANSPORTER
IC50
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
BINDER->LIGAND
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
OFF TARGET->NON-INHIBITOR
NON-INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
Related Record Type Details
METABOLITE -> PARENT
Trace in feces
URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
URINE
PARENT -> METABOLITE ACTIVE
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC